WAYNE, Pa., June 12, 2019 — Zyla Life Sciences (OTCQX:ZCOR) (“Zyla”), a growing commercial-stage life sciences company, announced the appointment of H. Jeffrey Wilkins, M.D. as senior vice president and chief medical officer (CMO) effective immediately.
“With extensive clinical development, medical affairs and product evaluation experience, Dr. Wilkins brings invaluable capabilities as we continue to grow Zyla Life Sciences,” said Bob Radie, president and chief executive officer. “Having worked both as a clinician and as a medical expert evaluating product opportunities, Dr. Wilkins provides us with an important new skill set to leverage.”
Dr. Wilkins most recently served as the chief medical officer at Lycera, a biotechnology company, where he led their clinical development of oncology and autoimmune products. Prior to joining Lycera, he served as clinical lead and partner at Nexeption Therapeutics, which works to bring together product opportunities, management teams and funding. Before Nexeption, Dr. Wilkins was CMO and head of medical affairs at Ceptaris Therapeutics which was purchased by Actelion. Prior to those positions, Dr. Wilkins held senior level positions at Cephalon and GlaxoSmithKline.
“The combination of the company’s robust portfolio of approved medications and desire to bring in new development-stage and approved products will give me an opportunity to add value with clinical knowledge and an understanding of products with significant market potential,” said Dr. Wilkins, senior vice president and CMO at Zyla Life Sciences. “This is an exciting time to join the company, as Zyla is poised for growth. I am looking forward to supporting the company’s important products and identifying additional medicines for patients and healthcare providers.”
Before working for life sciences companies, Dr. Wilkins was in clinical practice for almost ten years. He founded and was chief executive officer of TriValley Primary Care, a 27-physician and seven-site primary care group. Dr. Wilkins has authored numerous scientific publications. He received his bachelor’s degree from Bucknell University and his medical degree from Temple University.
About Zyla Life Sciences
Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers. Zyla is focused on marketing its portfolio of medicines for pain and inflammation. The company portfolio includes seven products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), TIVORBEX®indomethacin), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only —CII.
For full prescribing information, boxed warnings and medication guides, please visit the following sites for each product: sprix.com, vivlodex.com, zorvolex.com, tivorbex.com, and oxaydo.com. Prescribing information, the boxed warning and medication guide for INDOCIN suppositories and oral suspension can be found at dailymed.nlm.nih.gov.
Statements included in this press release that are not historical in nature and contain the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “look forward to” and other similar expressions are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations and are subject to known and unknown uncertainties and risks. Actual results could differ materially from those discussed due to a number of factors, including, but not limited to: our ability to continue as a going concern; the impact of our bankruptcy on our business going forward, including with regard to relationships with vendors and customers, employee attrition, and the costs and expenses resulting from our bankruptcy; the impact of our acquisition of five products from Iroko Pharmaceuticals, Inc., including our assumption of related liabilities, potential exposure to successor liability and credit risk of Iroko and its affiliates; our estimates regarding expenses, future revenues, capital requirements and needs for additional financing; our current and future indebtedness; our ability to maintain compliance with the covenants in our debt documents; the level of commercial success of our products; our ability to execute on our sales and marketing strategy, including developing relationships with customers, physicians, payors and other constituencies; the rate and degree of market acceptance of any of our products; the success of competing products that are or become available; the entry of any generic products for any of our products, or any delay in or inability to reformulate SPRIX; recently enacted and future legislation and regulations regarding the healthcare system; the accuracy of our estimates of the size and characteristics of the potential markets for our products and our ability to serve those markets; our failure to recruit or retain key personnel, including our executive officers; obtaining and maintaining intellectual property protection for our products; our ability to operate our business without infringing the intellectual property rights of others; our ability to integrate and grow any businesses or products that we may acquire; the outcome of any litigation in which we are or may be involved; general market conditions; and other risk factors set forth in Zyla’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the United States Securities and Exchange Commission (SEC) and in other filings Zyla makes with the SEC from time to time. While Zyla may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to update or revise any forward-looking-statements contained in this press release whether as a result of new information or future events, except as may be required by law.
SOURCE Zyla Life Sciences